Scott Jackson
Director/Board Member presso MACROGENICS, INC.
Patrimonio netto: 15 750 $ in data 31/03/2024
Profilo
Mr. Scott T.
Jackson is a Chairman at Mural Oncology Plc, an Independent Director at Spero Therapeutics, Inc., an Independent Director at GlycoMimetics, Inc. and an Independent Director at MacroGenics, Inc. He is on the Board of Directors at Spero Therapeutics, Inc., GlycoMimetics, Inc. and MacroGenics, Inc. Mr. Jackson was previously employed as a Trustee-Eastern Pennsylvania Chapter by The Leukemia & Lymphoma Society, Inc., a Chief Executive Officer & Director by Celator Pharmaceuticals, Inc., a Vice President-Marketing by YM BioSciences, Inc., a Vice President-Marketing by Eximias Pharmaceutical Corp., a Principal by Centocor, Inc., a Principal by Eli Lilly & Co., a Principal by ImClone LLC, and a Principal by Smithkline Beecham Plc.
He received his undergraduate degree from Philadelphia College of Pharmacy and an MBA from the University of Notre Dame.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0.01% | 15/03/2024 | 5 250 ( 0.01% ) | 15 750 $ | 31/03/2024 |
SPERO THERAPEUTICS, INC.
-.--% | 08/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
MACROGENICS, INC.
-.--% | 22/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Scott Jackson
| Società | Posizione | Inizio |
|---|---|---|
| MACROGENICS, INC. | Director/Board Member | 25/01/2017 |
| GLYCOMIMETICS, INC. | Director/Board Member | 28/11/2018 |
| SPERO THERAPEUTICS, INC. | Director/Board Member | 16/04/2020 |
Precedenti posizioni note di Scott Jackson
| Società | Posizione | Fine |
|---|---|---|
The Leukemia & Lymphoma Society, Inc.
 The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Corporate Officer/Principal | 01/06/2019 |
| CELATOR PHARMACEUTICALS INC | Chief Executive Officer | 12/07/2016 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Sales & Marketing | 01/05/2007 |
Eximias Pharmaceutical Corp.
 Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Eximias Pharmaceutical Corp. develops pharmaceuticals for treatment of cancer disorders. It offers its services in the mid-Atlantic areas. The company is headquartered in Berwyn, PA. | Sales & Marketing | 01/01/2006 |
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Corporate Officer/Principal | 01/07/2004 |
Formazione di Scott Jackson
| University of Notre Dame | Masters Business Admin |
| Philadelphia College of Pharmacy | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| MACROGENICS, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| SPERO THERAPEUTICS, INC. | Health Technology |
| Aziende private | 7 |
|---|---|
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Eximias Pharmaceutical Corp.
Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Eximias Pharmaceutical Corp. develops pharmaceuticals for treatment of cancer disorders. It offers its services in the mid-Atlantic areas. The company is headquartered in Berwyn, PA. | Health Technology |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Commercial Services |
- Borsa valori
- Insiders
- Scott Jackson
